Drug Type Monoclonal antibody |
Synonyms Anti-c-MET-monoclonal-antibody-Eli-Lilly, c-MET monoclonal antibody - Eli Lilly, c-MET-mAb-Eli-Lilly + [4] |
Target |
Action inhibitors |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Emibetuzumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 2 | United States | 07 Mar 2014 | |
Gastroesophageal junction adenocarcinoma | Phase 2 | United States | 07 Mar 2014 | |
Hepatocellular Carcinoma | Phase 2 | United States | 07 Mar 2014 | |
Renal Cell Carcinoma | Phase 2 | United States | 07 Mar 2014 | |
stomach adenocarcinoma | Phase 2 | United States | 07 Mar 2014 | |
metastatic non-small cell lung cancer | Phase 2 | United States | 28 Aug 2013 | |
metastatic non-small cell lung cancer | Phase 2 | Denmark | 28 Aug 2013 | |
metastatic non-small cell lung cancer | Phase 2 | France | 28 Aug 2013 | |
metastatic non-small cell lung cancer | Phase 2 | Germany | 28 Aug 2013 | |
metastatic non-small cell lung cancer | Phase 2 | Italy | 28 Aug 2013 |
Phase 2 | - | hcddmykahl(urpbmjzchu) = wbvkbbzbtd bpdqjogrdm (clbqfjwbls ) View more | Positive | 01 Jan 2020 | |||
hcddmykahl(urpbmjzchu) = jgxiiygfjh bpdqjogrdm (clbqfjwbls ) View more | |||||||
Phase 1/2 | Advanced cancer MET Positive | 97 | inleskggrw(fmwrlkrgcy) = Common adverse events were primarily mild or moderate and included fatigue (36.1%), peripheral edema (28.9%), and nausea (14.4%). rnjtsoabbq (xmpiibdlmm ) View more | Positive | 01 Sep 2019 | ||
(pts with HCC) | |||||||
NCT01874938 (Pubmed) Manual | Phase 2 | c-Met positive Stomach Cancer MET Positive | 15 | xvorfhvghv(oulxrbjueo) = uqkutjbzfd hcjwcsmgfh (feiwbkjgku, 33 - 59) View more | Negative | 01 Dec 2017 | |
Phase 1/2 | 97 | qwcfxnuswd(bfumkgjrwo) = Common possibly related AEs of all grades included dyspnea (16%) yxpqmrihjc (puhyaybfqd ) View more | - | 01 Jul 2017 | |||
Phase 1 | 37 | (solid tumors) | ciguxrqbqq(vtvfnrgdkb) = Twenty-three patients with solid tumors received emibetuzumab monotherapy at 20, 70, 210, 700, 1,400, and 2,000 mg and 14 non-small cell lung cancer (NSCLC) patients at 700, 1,400, and 2,000 mg in combination with erlotinib 150 mg daily. gpzhbtczoj (laeycbfkug ) View more | Positive | 15 Apr 2017 | ||
(NSCLC) | |||||||
NCT01900652 (ASCO2016) Manual | Phase 2 | c-Met positive non-small cell lung cancer MET Positive | 111 | mwgkphwhdn(wdefbmmgwn) = icouwnnahq zaqtuphqfp (mfjqwbaiqz ) View more | Positive | 04 Jun 2016 | |
mwgkphwhdn(wdefbmmgwn) = blvczcrelj zaqtuphqfp (mfjqwbaiqz ) View more |